Genomic analysis of plasma cell-free DNA in patients with cancer

JAMA Oncology

Volumn 3, Issue 6, 2017, Pages 740-741

  Oxnard, Geoffrey R ^a,b   Paweletz, Cloud P ^a   Sholl, Lynette M ^b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL FREE NUCLEIC ACID;

GENETIC MARKER; GENETICS; GENOTYPING TECHNIQUE; HUMAN; NEOPLASM; PROCEDURES;

CELL-FREE NUCLEIC ACIDS; GENETIC MARKERS; GENOTYPING TECHNIQUES; HUMANS; NEOPLASMS;

EID: 85010438524     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2016.2835     Document Type: Note

References (7)

1. Crowley E, Di Nicolantonio F, Loupakis F, Bardelli A. Liquid biopsy: monitoring cancer-genetics in the blood. Nat RevClin Oncol. 2013; 10(8):472-484.
2. Sacher AG, Paweletz C, Dahlberg S.E., et al. Prospective validation of rapid plasma genotyping for the detection of EGFR and KRAS mutations in advanced lung cancer [published online April 7, 2016]. JAMA Oncol. doi:10.1001/jamaoncol.2016.0173.
3. Thress KS, Paweletz CP, Felip E, et al Acquired EGFRC797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat Med. 2015; 21(6):560-562.
4. Douillard J-Y, Ostoros G, Cobo M, et al. Gefitinib treatment in EGFR mutated caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR status. J Thorac Oncol. 2014; 9(9):1345-1353.
5. Schwaederle M, Husain H, Fanta P.T., et al. Detection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor cell DNA assay. Oncotarget. 2016; 7(9): 9707-9717.
6. Tabernero J, Lenz H-J, Siena S, et al Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial. Lancet Oncol. 2015; 16(8):937-948.
7. Oxnard GR, Thress KS, Alden R, et al Association between plasma genotyping and outcomes of treatment with osimertinib (AZD9291) in advanced non-small-cell lung cancer [published online Jun 27, 2016]. J Clin Oncol. doi:10.1200/JCO.2016.66.7162.